Dosing Protocols Research

Reported dosing ranges for research peptides, compiled from published studies, practitioner protocols and Dr. Trevor reports. Every range is labeled with its source type and evidence strength. Sources vary.

See the peptide dosage chart Open the peptide calculator

How this research is compiled

  • Published study: amounts used in published human trials in the PeptideWhiz study library, linked to each study page and PubMed.
  • Practitioner protocols: ranges listed in published practitioner dosing protocols.
  • Dr. Trevor reports: amounts mentioned in transcribed videos by Dr. Trevor.

Compounds

  • Retatrutide dosage: Reported in research: 0.5–12 mg once weekly (subcutaneous) in published human trials; practitioner protocols report 1–12 mg per week. Sources vary.
  • Semaglutide dosage: Reported in research: 0.25–2.4 mg once weekly (injection) and 3–14 mg once daily (oral tablet) in published human trials; practitioner protocols report 250 mcg–2.5 mg weekly. Sources vary.
  • Tirzepatide dosage: Reported in research: 5–15 mg once weekly (subcutaneous) in published human trials; a practitioner protocol lists 2.5 mg and 8 mg weekly. Sources vary.
  • BPC-157 dosage: Reported in research: 200–750 mcg daily in practitioner protocols, and 500 mcg–1 mg daily in Dr. Trevor reports. No human-trial dose is reported in our study library. Sources vary.
  • TB-500 dosage: Reported in research: 2–5 mg once or twice weekly in most practitioner protocols (one source lists 500–1,000 mcg daily), and 2.5 mg twice weekly to 5 mg every five days in Dr. Trevor reports. No human-trial dose is reported in our study library. Sources vary.
  • CJC-1295 / Ipamorelin dosage: Reported in research: ipamorelin 100–300 mcg daily and CJC-1295 (no DAC) 100–300 mcg daily in practitioner protocols; CJC-1295 with DAC is listed at 300–1,000 mcg twice weekly or 2 mg weekly. No human-trial dose for the pair is reported in our study library. Sources vary.
  • GHK-Cu dosage: Reported in research: 1–2 mg daily in practitioner protocols, and 1–3 mg daily in Dr. Trevor reports. No human-trial dose is reported in our study library. Sources vary.
  • MOTS-c dosage: Reported in research: 200–1,500 mcg once daily or 5–10 mg every five days in practitioner protocols, and 1 mg daily to 5 mg twice weekly in Dr. Trevor reports. No human-trial dose is reported in our study library. Sources vary.
  • Cagrilintide dosage: Reported in research: 0.3–4.5 mg once weekly (subcutaneous) in published human trials, with 2.4 mg the amount used in the phase 3 trials; practitioner protocols report 300 mcg–4.5 mg weekly. Sources broadly agree.
  • Tesamorelin dosage: Reported in research: 1–2 mg once daily (subcutaneous) in published human trials, most often 2 mg; practitioner protocols report 1–2 mg daily. Sources broadly agree.

FAQ

What is Dosing Protocols Research?

A PeptideWhiz section that lists reported dosing ranges for peptides, with the source type and evidence strength of each range. It does not recommend an amount for any person.

Where do the ranges come from?

Published human trials in the PeptideWhiz study library, practitioner protocols, and Dr. Trevor reports. Each range is labeled with its source type.

Why do sources disagree?

Studies and protocols differ in the people involved, the form used, the goal and the time frame. Where sources disagree, each range is shown separately.

Last updated: November 2, 2026.

Research information only. This page lists amounts as reported in published studies, practitioner protocols and Dr. Trevor reports. It is not medical advice and not a recommendation for any person. Sources vary, and most of these compounds are not approved for the uses discussed.